Compare IGA & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGA | EDAP |
|---|---|---|
| Founded | 2005 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 128.9M |
| IPO Year | N/A | 1998 |
| Metric | IGA | EDAP |
|---|---|---|
| Price | $9.66 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 61.3K | 25.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $9.21 | $1.21 |
| 52 Week High | $10.12 | $5.05 |
| Indicator | IGA | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 34.74 |
| Support Level | $9.39 | $3.14 |
| Resistance Level | $9.67 | $3.44 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 55.87 | 13.79 |
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.